<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847635</url>
  </required_header>
  <id_info>
    <org_study_id>PASCAL-RPD</org_study_id>
    <nct_id>NCT04847635</nct_id>
  </id_info>
  <brief_title>Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration</brief_title>
  <acronym>PASCAL-RPD</acronym>
  <official_title>Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione G.B. Bietti, IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Genova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, controlled, longitudinal, interventional multicentric study&#xD;
      involving patients with reticular pseudodrusen secondary to AMD.&#xD;
&#xD;
      The objective of this study is to establish the effectiveness of subthreshold laser treatment&#xD;
      in increase/prevent the decrease of the retinal sensibility in patients with reticular&#xD;
      pseudodrusen, and to reduce the progression of RPD to atrophy.&#xD;
&#xD;
      Approximately 50 naïve patients with reticular pseudodrusen who underwent subthreshold laser&#xD;
      treatment in perifoveal area. These patients should be randomized in the 2 study arms of the&#xD;
      study. Patients will be evaluated at Screening/Baseline and then revaluated and retreated at&#xD;
      month 3, 6 and 9. At month 12, all patients will be evaluated with a full ocular examination,&#xD;
      visual acuity measurement (VA), optical coherence tomography (OCT) with autofluorescence,&#xD;
      OCT-angiography and microperimetry.&#xD;
&#xD;
      The rationale of the study is to prevent the evolution of reticular pseudodrusen to atrophic&#xD;
      degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, longitudinal, interventional study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the retinal sensitivity - 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Functional changes in the retinal sensitivity on customized microperimetry from day 0 to month 12 (unit of measure: dB)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anatomical changes using structural optical coherence tomography (OCT)</measure>
    <time_frame>12 months</time_frame>
    <description>Anatomical changes will be evaluated with retinal thickness (unit of measure: microns)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Progression</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of progression to advance AMD (GA and/or neovascular AMD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the retinal sensitivity - 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Functional changes in the retinal sensitivity on customized microperimetry from day 0 to month 6 (unit of measure: dB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomical changes using fundus autofluorescence (FAF)</measure>
    <time_frame>12 months</time_frame>
    <description>Anatomical changes will be evaluated analyzing the development of geographic atrophy using FAF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic influence (% of AMD-associated single-nucleotide polymorphism (SNP) in treated patients)</measure>
    <time_frame>12 months</time_frame>
    <description>The % of AMD-associated single-nucleotide polymorphism (SNP) will be evaluated analyzing the % of patients with an AMD-associated SNP in patients showing no progression vs progression to advance AMD (main outcome 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomical changes using OCT-angiography (OCT-A)</measure>
    <time_frame>12 months</time_frame>
    <description>Anatomical changes will be evaluated analyzing the perfusion density by means of OCT-A</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Macular Degeneration, Senile</condition>
  <condition>Laser Burn of Retina</condition>
  <condition>Macular Degeneration Intermediate</condition>
  <condition>Macular Degeneration, Dry</condition>
  <arm_group>
    <arm_group_label>Subthreshold laser group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the efficacy of Subthreshold laser in the treatment of reticular pseudodrusen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The light from the retinal illumination system on the laser device will be used instead of the laser beam in all follow-up evaluations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)</intervention_name>
    <description>The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.</description>
    <arm_group_label>Subthreshold laser group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)</intervention_name>
    <description>The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.</description>
    <arm_group_label>Sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  50 years or older&#xD;
&#xD;
          -  Presence of RPD secondary to AMD&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) between 20/20 and 20/400 inclusive&#xD;
&#xD;
          -  Clear ocular media&#xD;
&#xD;
          -  Ability to provide informed consent and attend all study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of Geographic Atrophy (GA)&#xD;
&#xD;
          -  Evidence of choroidal neovascularization in either eye&#xD;
&#xD;
          -  Any prior treatment for AMD, aside from antioxidants&#xD;
&#xD;
          -  Any corneal opacity, cataract formation and hemorrhage in the vitreous body, which may&#xD;
             interfere with viewing by the laser surgeon of the target structures&#xD;
&#xD;
          -  Aphakic eye with vitreous in the anterior chamber&#xD;
&#xD;
          -  Neovascular Glaucoma&#xD;
&#xD;
          -  Glaucoma caused by congenital angle anomalies&#xD;
&#xD;
          -  Open angle of less than 90º or extensive peripheral anterior and low synechia, present&#xD;
             circumferentially around the corner&#xD;
&#xD;
          -  Significant corneal edema or reduced water clarity that obscures the view angle in&#xD;
             detail&#xD;
&#xD;
          -  Glaucoma secondary to active uveitis&#xD;
&#xD;
          -  Any other ocular condition that would progress in the study period and confound visual&#xD;
             acuity assessment&#xD;
&#xD;
          -  Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve&#xD;
             Presence of idiopathic or autoimmune-associated uveitis&#xD;
&#xD;
          -  Any intraocular surgery 3 months of entry&#xD;
&#xD;
          -  Any prior thermal laser in the macula&#xD;
&#xD;
          -  History of vitrectomy, filtering surgery, corneal transplant or retinal detachment&#xD;
             surgery&#xD;
&#xD;
          -  Previous therapeutic radiation in the ocular region in either eye&#xD;
&#xD;
          -  Any treatment with an investigational agent in the previous 60 days before study entry&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women less than 1 year postmenopausal&#xD;
             or less than 6 weeks since sterilization (further definition can be found in Section&#xD;
             12.7) at Baseline, unless they are using highly effective methods of contraception&#xD;
             during dosing of study treatment.&#xD;
&#xD;
          -  Participation in an investigational drug, biologic, or device study within 6 Months&#xD;
             prior to Baseline [Note: observational clinical studies solely involving&#xD;
             over-the-counter vitamins, supplements, or diets are not exclusionary&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Querques, MD, PhD</last_name>
    <phone>+390226434004</phone>
    <email>querques.giuseppe@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massimo Nicolò</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Nicolò, MD</last_name>
      <phone>+390103538469</phone>
      <email>massimonicolo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Giuseppe Querques</name>
      <address>
        <city>Milan</city>
        <zip>20134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Querques, MD, PhD</last_name>
      <phone>+390226434004</phone>
      <email>querques.giuseppe@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Querques, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riccardo Sacconi, MD, FEBO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Borrelli, MD, FEBO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federico Ricci</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Ricci, MD</last_name>
      <phone>+390620903348</phone>
      <email>federico.ricci@uniroma2.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mariacristina Parravano</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariacristina Parravano</last_name>
      <phone>+390685356727</phone>
      <email>mcparravano@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Querques G, Sacconi R, Gelormini F, Borrelli E, Prascina F, Zucchiatti I, Querques L, Bandello F. Subthreshold laser treatment for reticular pseudodrusen secondary to age-related macular degeneration. Sci Rep. 2021 Jan 26;11(1):2193. doi: 10.1038/s41598-021-81810-7.</citation>
    <PMID>33500505</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Raffaele</investigator_affiliation>
    <investigator_full_name>Querques Giuseppe</investigator_full_name>
    <investigator_title>Head of Medical Retina &amp; Imaging Unit, Clinical Professor, and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Retina</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Reticular pseudodrusen</keyword>
  <keyword>Sub-threshold laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

